VENENUM Biodesign's main focus is on discovering innovative medicines for cancer, inflammation, infectious diseases, metabolic diseases, and women's health. They have advanced programs targeting Clostridium difficile infection and Type 2 Diabetes. Their business model involves creating high-value small molecule programs and collaborating with partners for clinical and commercial development. Their goal is to improve patients' lives through the discovery of therapeutic compounds. They utilize advanced screening techniques and compound libraries to identify potential drug candidates. VENENUM Biodesign is part of the Genesis Biotechnology Group, which is dedicated to discovering new medicines for unmet medical needs.